Free Trial
NASDAQ:HURA

TuHURA Biosciences (HURA) Stock Price, News & Analysis

TuHURA Biosciences logo
$4.79 +0.06 (+1.27%)
As of 01/17/2025 04:00 PM Eastern

About TuHURA Biosciences Stock (NASDAQ:HURA)

Key Stats

Today's Range
$4.60
$5.14
50-Day Range
$3.02
$6.68
52-Week Range
$2.84
$14.60
Volume
115,329 shs
Average Volume
234,542 shs
Market Capitalization
$202.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Buy

Company Overview

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Receive HURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TuHURA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HURA Stock News Headlines

TuHURA Biosciences Inc HURA
WARNING: “Buffett Indicator” flashing for first time in 50 years
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
TuHURA Biosciences to Acquire Kineta, Inc. in 2025
TuHURA Biosciences enters definitive merger agreement to acquire Kineta
See More Headlines

HURA Stock Analysis - Frequently Asked Questions

TuHURA Biosciences' stock was trading at $4.09 at the beginning of the year. Since then, HURA shares have increased by 17.1% and is now trading at $4.79.
View the best growth stocks for 2025 here
.

Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
1/20/2025
Next Earnings (Estimated)
2/12/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HURA
Previous Symbol
NASDAQ:HURA
Web
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$15.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+171.4%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-8,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($4.11) per share

Miscellaneous

Free Float
42,200,000
Market Cap
$202.55 million
Optionable
N/A
Beta
0.92
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:HURA) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners